Clerkenwell Health

Trial of new psychedelic drug seeks patients with treatment resistant depression

7 February 2024 – London, UK – An international clinical trial which is investigating a novel synthetic formulation of the psychedelic substance 5-MeO-DMT (also known as Mebufotenin) for Treatment Resistant Depression (TRD) has expanded into a new London location – and is seeking suitable candidates. Clerkenwell Health – a company delivering clinical trials for the...